Objective-Intermedin plays an important role in vascular remodeling and significantly improves blood perfusion, but the precise mechanism remains unclear. Herein, we aimed to define whether vascular lumen enlargement is responsible for the intermedin-increased blood perfusion and explore the underlying cellular and molecular mechanisms. Approach and Results-To study the role of intermedin, we generated the IMD-KO (Adm2 −/− ) mice using CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9) system. Intermedin significantly promoted vascular lumen enlargement in vitro (fibrin beads assay) and in vivo (murine retinas), which contributed to the improved blood perfusion in both physiological (retinal) and pathological (tumor) angiogenic models. We designed experiments to calculate the endothelial cell (EC) size and found that the lumen enlargement is because of EC proliferation but not because of a change in cell shape. ECs that construct vessel walls are considered quiescent cells because they are in a state of contact inhibition and show reduced responsiveness to VEGF (vascular endothelial growth factor). Using immunoprecipitation, Western blot assay, and fluorescent microscopy, we found that intermedin induced the formation of a signaling complex containing CRLR (calcitonin receptor-like receptor)/β-arr1 (β-arrestin1)/Src in ECs and promoted it internalizing into cytoplasm in a clathrin-dependent manner to activate downstream ERK1/2 (extracellular signal-regulated kinase 1/2). Importantly, this effect was not abrogated by cell-cell contacts of ECs. Through this mechanism, intermedin could reactivate the quiescent ECs to proliferate, resulting in continuous lumen expanding and a more effective blood perfusion. Conclusions-Our findings suggest a novel mechanism that may explain how quiescent ECs overcome the contact inhibition and regain the ability to proliferate for continuous vascular lumen enlargement. Visual Overview-An online visual overview is available for this article. 
A ngiogenesis-the formation of new blood vessels from preexisting vasculature-is important in certain pathologies, particularly in ocular neovascular diseases 1 and cancer. [2] [3] [4] However, although most tumors are highly vascularized, the tumor vasculature is highly abnormal and dysfunctional, containing a large amount of low-perfused or nonperfused vessel sprouts. [5] [6] [7] Most neovessels generated by angiogenesis, especially those in tumor cores, are poorly lumenized or do not have any lumen at all. Thus, the low perfusion rate of tumors is likely due not to a decreased number of vessels but rather to the narrow lumens of tumor vessels, which severely restrict the amount of blood flow.
Intermedin, also named adrenomedullin 2 (Adm2), is a member of the calcitonin family. 8 Intermedin has been reported to play roles in cancer pathology [9] [10] [11] and angiogenesis. 12 Our previous study has revealed that intermedin promotes dramatic remodeling of the vasculature into a hierarchical architecture, containing well-organized vessels with wider lumens, and it significantly improves tumor blood perfusion. 13 Because the number of neovessels is significantly reduced after intermedin treatment, 13, 14 we hypothesized that vascular lumen enlargement may play an important part in the effect of intermedin in increasing blood perfusion.
The process of lumen formation is a key step in angiogenesis because it is crucial for the formation of a hierarchical and well-perfused vasculature. 15 Much research has aimed to increase the understanding of this process, but studies have primarily focused on the initial stage when neovessels form primitive lumens. It is known that a change in the shape of endothelial cells (ECs) is the major cause of the opening of primitive lumens. [16] [17] [18] However, little is known about the later stage when established lumens become further enlarged for the establishment of a hierarchical and functional vasculature. 16, 17 The EC shape change might still underlie the changes that occur at this stage. However, if ECs continue stretching to fit the increasing lumen diameters of growing vessels, one would expect to observe a large number of ECs with increased sizes covering enlarged vessels. However, there is no evidence demonstrating that the enlarged vessels are composed of enlarged ECs. Thus, it is possible that vessels expand their lumens in other ways, such as by increasing the EC number via cell proliferation.
VEGF (vascular endothelial growth factor) is considered the most important growth factor in angiogenesis. It promotes EC proliferation by inducing VEGFR2 (vascular endothelial growth factor receptor 2) phosphorylation and activating downstream ERK1/2 (extracellular signal-regulated kinase 1/2). 19 However, ECs that construct vessel walls remain in physical contact with each other, causing them to be in a state of contact inhibition and to have a low proliferative response to VEGF. 4, [17] [18] [19] If the lumens of established vessels become enlarged via an increase in EC number, then quiescent ECs must proliferate continuously. This paradox indicates that a VEGF-independent mechanism may exist by which quiescent ECs circumvent the contact inhibition and regain the ability to proliferate.
It is not known whether intermedin affects the proliferation of ECs. However, intermedin is capable of inducing the phosphorylation of ERK1/2 in ECs through an unidentified mechanism. 12, 13 Because ERK1/2 activation is a well-established signal that promotes EC proliferation, we anticipated that intermedin might affect vascular lumen enlargement via EC proliferation by regulating ERK1/2. Intermedin shares CRLR (calcitonin receptor-like receptor), which is a class B GPCR (G protein-coupled receptor), with other family members. 8 However, the manner by which intermedin regulates CRLR and whether it is responsible for downstream ERK1/2 activation are still unknown.
In this study, we have shown that intermedin increases effective blood perfusion via vascular lumen enlargement and that this effect is because of an increase in EC number and not because of a change in cell shape. Intermedin potently promotes quiescent EC proliferation through ERK1/2 activation, resulting in increases in EC number and lumen diameter. In addition, it induces the formation of a signaling complex containing CRLR, β-arr1 (β-arrestin1), and Src in ECs. This complex is internalized into the cytoplasm in a clathrin-dependent manner and eventually activates the ERK1/2 signaling cascade. Importantly, this process is not abrogated by cell-cell contact. Thus, our findings indicate a novel mechanism by which quiescent ECs overcome contact inhibition and regain the ability to proliferate continuously for lumen enlargement. Through this mechanism, intermedin could expand vessel lumens by increasing the EC number, leading to more effective blood perfusion. The general importance of intermedin in vascular remodeling, that is, in increasing blood perfusion by vascular lumen enlargement via quiescent EC proliferation, indicates that it has potential for use in a novel therapeutic strategy for angiogenesis-associated diseases.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Intermedin Promoted Vascular Lumen Enlargement, Which May Have Contributed to Improved Blood Perfusion
In this study, we tested the hypothesis that intermedin may promote lumen enlargement using IMD knockout mice. We used the CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9) system to generate the IMD-KO (Adm2 −/− ) mice (No. 27 line; Figure I in the online-only Data Supplement). The neonatal mouse retina develops a stereotypical vasculature, and thus, it is a good model for the study of angiogenesis. Retinas were collected from mice on the first postnatal week and examined by staining with IB4 (isolectin B4). The Adm2 −/− mice were ostensibly viable and fertile ( Figure IF in the online-only Data Supplement). However, analysis of the retinal vasculature on postnatal day 6 revealed that the diameters of the retinal vessels, including the capillaries, venules, and arterioles, were markedly decreased in the KO mice compared with those in the WT mice ( Figure 1A through 1D). Administration of intermedin from postnatal days 2 to 5 increased the mean lumen diameter in both of the WT and KO groups, whereas treatment with an anti-intermedin monoclonal antibody decreased it (Figure 1A through 1D; Figure II in the online-only Data Supplement). We also performed time course analysis to measure the dynamic increase in the lumen diameter by fibrin bead assay (from day 9 to day 18) and found that intermedin significantly promoted enlargement of the lumens of preexisting vessels ( Figure 1E ). This effect was abrogated by the competitive antagonist IMD ( Figure 1F ). Lumen enlargement was also inhibited by the silencing of endogenous intermedin ( Figure IIIA through IIIC in the online-only Data Supplement). We then asked whether the improved blood perfusion was because of the intermedin-promoted lumen enlargement. To determine the inner lumen size that allows blood to flow through, FITC (fluorescein isothiocyanate)-conjugated dextran was injected through left ventricle to label perfused vessels. The intermedin-induced larger retinal arterioles also had an increased inner lumen diameter that allowed for more blood to flow through, whereas the absence of intermedin resulted in decreases in both the outer and inner lumen diameters, leading to impaired blood perfusion (Figure 2A and 2B).
Nonstandard Abbreviations and Acronyms
Although highly vascularized, the tumor vasculatures are often poorly perfused. We have previously shown that intermedin significantly improves tumor blood perfusion. 13 Because intermedin also restricts vessel branching and reduces vessel density, 13, 14 intermedin may increase tumor blood perfusion by expanding the diameters of tumor vessel lumens. Indeed, the intermedin administration increased the lumen diameter of CT26 tumors by ≈35%. In contrast, intermedin and anti-intermedin monoclonal antibody decreased the lumen diameter by ≈37% and 39%, respectively ( Figure 2C and 2D) . ) . B-D, The retinal vessel diameters were quantified as described in Materials and Methods. The mean vessel diameter of each group is presented relative to that of the control (the mean diameter was calculated across the entire retina, not only in a selected region, and the statistical data and SDs were calculated across multiple retinas; n=5 retinas per group). E, Fibrin bead assay was performed in the presence or absence of IMD (2 μM) from days 9 to 18. F, Increases in the lumen diameters of 5 randomly chosen vessels from 1 well were measured, and the mean was calculated; n=6 (wells). Three independent experiments were performed in duplicate wells, and the SD was calculated across multiple wells. Data were presented as means±SD and analyzed using 1-way ANOVA (Kruskal-Wallis test) followed by the nonparametric Dunn post hoc analysis. *P<0.05, **P<0.01, ***P<0.001. We further assessed the lumen diameters in IMD-KO mice. The mean diameter of the perfused vessels was decreased by ≈31% in the IMD-KO mice ( Figure 2E and 2F). Intermedin administration rescued the defect of lumen enlargement and increased the inner lumen diameter that allows blood flow to the level of the WT mice ( Figure 2E and 2F) . Those results demonstrated that intermedin strongly promoted vessel lumen enlargement, which contributed to the improvement of tumor blood perfusion. Similar to our previous observation that the tumor growth was inhibited by the intermedin inhibitors, 13 the tumor growth rate in the IMD-KO mice was slower than that in the WT mice ( Figure 2G ). The volume of the tumor in IMD-KO mice at the end point of the experiment was significantly smaller than that in the WT mice ( Figure 2H ). The administration of intermedin accelerated the tumor growth in the IMD-KO mice, resulting in comparable tumor volume to that in the WT mice ( Figure 2G and 2H) . The results suggested that intermedin deletion resulted in insufficient tumor blood supply and inhibited the growth of tumor.
Considering the CRISPR/Cas9 system may cause offtarget effects, we also examined the vascular phenotype of an additional IMD-KO (Adm2 
Lumen Enlargement Was Because of an Increase in EC Number and Not Because of a Change in Cell Shape
In the process of lumen enlargement, if ECs continue stretching to fit the increasing lumen diameters, then the surface areas of the ECs should increase accordingly. To determine whether the EC shape change is responsible for lumen enlargement, we used fibrin beads (in vitro) and retina (in vivo) models to calculate the mean surface area of ECs ( Figure 3A and 3B) using the formula S=L×(πR)/N, where S represents the mean surface area, L represents the length of the vessel of interest, R represents the diameter, and N represents the nuclei number ( Figure 3A , bottom). The retinal vessels of neonatal mice were examined by double staining with IB4 and an endothelial nuclear marker, ERG (erythroblast transformation-specific related gene; Figure 3B ). No differences in mean EC size were observed between the vehicle-and intermedin-treated vessels in both the in vitro and in vivo models ( Figure 3C through 3E ). In addition, no difference was detected between WT and KO mice, and neither intermedin nor anti-intermedin monoclonal antibody affected the mean EC size. Linear regression analysis revealed that the lumen diameter was nearly proportional to the EC number but not to the EC size ( Figure 3F through 3H), indicating that the increased EC number was the major cause of the vascular lumen enlargement.
There was a possibility that the vasodilatory effect of intermedin may contribute to the vessel expansion. However, we found that the blood pressure between the WT and IMD-KO mice had no significant difference, which may be because the baseline level of intermedin in the circulation of normal mice is much lower than the level that is able to affect the blood pressure ( Figure VII in the online-only Data Supplement). We also checked the vascular morphology at the leading front of retinal vasculature. As shown in Figure 3I and 3J, the deletion of intermedin resulted in increased vessel sprouting, which is consistent with our previous observation. 13 One may assume that the small lumens may be a nonspecific effect resulted from the increased vessel sprouting. However, no significant difference was found in the diameter among the neovessels at the leading front that only contain 1 nucleus ( Figure 3K ). Most neovessels at the leading front had only 1 cell nucleus, suggesting that their vessel lumen was constructed by only 1 EC. Thus, the vascular lumens constructed by only 1 EC should have similar diameter. This is consistent with our observations ( Figure 3I through 3K) and consistent with the conclusion that the lumen diameter was determined by the EC number but not by the EC shape changes.
A mere lumen enlargement without vessel stabilization would lead to vessel leakage. As we know, the vascular functionality is reliant on pericyte coverage of the vascular sprouts for vessel stabilization and maturation. 20, 21 We, therefore, investigated whether intermedin affected the recruitment of pericytes to nascent vessels during tumor angiogenesis. Double-labeling of CD31 and α-SMA (α-smooth muscle actin)-a pericyte/VSMC (vascular smooth muscle cell) marker 22 -revealed that the pericyte coverage of tumor vessels was markedly reduced in IMD-KO mice compared with the WT mice. The administration of intermedin peptide rescued this defect, resulting in fine pericyte coverage ( Figure 3L and 3M). The results suggest that intermedin may facilitate the vessel maturation via pericyte recruitment, and loss of intermedin may lead to vessel instability and vascular leakage. In fact, the deletion of intermedin markedly increased the vascular leakage, whereas the systematic administration , and Adm2 −/− mice rescued by IMD injection were similarly perfused using FITC-dextran. The samples were cryosectioned at 120 μm thickness, stained for CD31, and observed after 3-dimensional reconstruction. D and F, The diameters of tumor vessels were measured as described in Materials and Methods. Vessels in 20 randomly chosen fields from 5 samples (4 fields from 1 sample) were measured and are presented as scatter plots with the mean±SEM. Each dot represents the diameter of a single vessel. G, The tumor volume was measured every 3 d; the growth curve in 24 d was shown as means±SD. H, The tumor volume at the end point of experiment (day 24 after tumor inoculation) was presented as scatter plots with means±SD (n=7) and analyzed using 1-way ANOVA (Kruskal-Wallis test) followed by the nonparametric Dunn post hoc analysis. *P<0.05, **P<0.01, ***P<0.001. , and WT mice treated with IMD or anti-IMD were stained with IB4 and ERG. The mean surface areas of ECs were quantified as described above (n=5). G and H, Linear regression analysis showed that the lumen diameter was nearly proportional to the EC number but not to the EC size. I, Retinas were double stained with IB4 and ERG. (Continued ) of intermedin could rescue this defect, reducing the baseline permeability and the VEGF-induced leakage in both IMD-KO and WT mice ( Figure 3N ). The results suggest that the intermedin-induced lumen enlargement is accompanied by the recruitment of pericytes and vascular stabilization. It is consistent with previous publications that intermedin plays a role in the maintenance of endothelial barrier function. 13, [23] [24] [25] Increased EC Number Was Because of Intermedin-Induced EC Proliferation
We then performed in vivo EdU proliferation assay to determine whether the increased cell number was because of EC proliferation. EdU/IB4 double staining showed that intermedin significantly promoted proliferation of the ECs that resided in the area proximal to the leading edge and in the vessel walls. In contrast, in the IMD-KO mice, EC proliferation was significantly decreased (Figure 4A and 4C) . Because the EdU-positive cells may have come from other retinal layers, we double stained the retinas with ERG and EdU to determine whether the proliferating cells were ECs. As shown in Figure 4B and 4D, injection of intermedin strongly promoted the proliferation of ERG-positive cells in the vessel stalk area. In contrast, the proliferation of these cells was substantially decreased in the IMD-KO mice.
In addition, double staining for EdU/IB4 showed that exogenous intermedin promoted the proliferation of cells located in the walls of large vessels ( Figure 4E and 4F) . Further, double staining for EdU/ERG revealed that the intermedin-induced proliferating cells were mainly ECs. In contrast, the proliferation of ERG-positive cells was substantially reduced in the KO mice ( Figure 4G and 4H). These results suggested that intermedin increased the number of ECs by promoting their proliferation.
We also examined the retinal vasculature in the adult mice (6 weeks of age). As expected, in the adult mice, the retinal vessel diameter of the IMD-KO mice was smaller than that of the WT mice ( Figure 4I and 4J ). However, this may be because the EC proliferation was lower in the KO mice in the developmental stage. We, therefore, examined whether the EC proliferation rate of the WT or KO adult mice was different. No sign of retinal EC proliferation was observed in either the adult WT or KO mice ( Figure 4K and 4L ). It suggests that the physiological concentration of intermedin in WT mice may not promote the adult ECs to proliferate. On the contrary, the injection of exogenous intermedin into the eye triggered the proliferation of ECs ( Figure 4K and 4L), indicating that high concentration of intermedin is able to stimulate the quiescent ECs to proliferate even in the adults.
ERK1/2 Activation Was a Critical Step in Intermedin-Mediated EC Proliferation
To form a functional vessel lumen, ECs must remain in physical contact with each other, which causes them to be in a state of contact inhibition and to have a low proliferative response to VEGF stimulation. 4, [17] [18] [19] We assessed whether contact inhibition of growth signal mimicry occurs after VEGF or intermedin treatment using confluent (cells surrounded by adjacent cells that formed cell-cell contacts with each other) and nonconfluent (cells that were sparse or were not completely surrounded by adjacent cells) human umbilical vascular ECs (HUVECs). The endothelial-specific junctional component VEC (VE-cadherin) was stained for visualization of cell-cell contacts ( Figure 5A through 5F ). Staining for Ki67 showed that VEGF markedly induced nonconfluent EC proliferation; however, this effect was significantly attenuated when the ECs grew to confluence. On the contrary, intermedin strongly promoted the proliferation of both sparse and confluent ECs ( Figure 5A through 5D ), in contrast with the effects of VEGF. The different growth rates observed at different stages indicated that intermedin promoted EC proliferation through a different mechanism than that of VEGF.
ERK1/2 activation is a critical step in EC proliferation. The confluent ECs responded poorly to VEGF compared with their nonconfluent counterparts, as indicated by the ERK1/2 phosphorylation pattern ( Figure 5E ), consistent with previous observations. 19, 26 In contrast, intermedin markedly increased the phosphorylation of ERK1/2 in both confluent and nonconfluent ECs ( Figure 5E ). Fluorescent staining for phospho-ERK1/2 showed similar results ( Figure 5F through 5I). The intermedin-induced ERK1/2 phosphorylation and EC proliferation could be blocked by an anti-intermedin monoclonal antibody ( Figure IX in the online-only Data Supplement). In addition, FR180204-a selective inhibitor of ERK1/2 27 -blocked the intermedin-induced ERK1/2 phosphorylation, EC proliferation, and lumen expansion in vitro (Figure X in the online-only Data Supplement). Importantly, when ERK1/2 signaling was blocked, the in vivo intermedin-induced retinal EC proliferation and retinal vessel enlargement were also inhibited ( Figure 5J and 5K ). These results demonstrate that ERK1/2 activation is a critical step in intermedin-mediated EC proliferation and lumen enlargement.
Intermedin Induced Formation of a Signaling Complex Composed of CRLR/β-arr1/Src
Intermedin has been reported to be an agonist of CRLR-a class B GPCR. 8 However, it is not known how intermedin regulates CRLR or how the signal is transduced downstream Figure 3 Continued. The representative images show the neovessel sprouts at the leading front. The green dots indicate the sprouting points, the magnified panels show the diameter of the neovessels that only contain 1 nucleus. J and K, The number of new sprouting points and the diameter of the neovessels at the leading front that contain 1 nucleus were quantified. Data were presented as means±SD (n=5). L, Lewis lung cancer (LL2/c) was established in the WT or Adm2 −/− mice. IMD administration (0.2 mg/kg per day, SC from 1-21 d after tumor inoculation) was used as rescue treatment in the KO mice. At the end point of the experiment, the tumor samples were collected and stained for CD31 (red) and α-SMA (α-smooth muscle actin; green). M, The staining density of α-SMA and CD31 was counted using the software Image-Pro Plus. The relative density of α-SMA signal referred to that of CD31 was quantified using 20 randomly chosen fields from 5 samples (4 fields from 1 sample). Data were presented as means±SD. N, The in vivo permeability assay (Miles assay) was performed as described in the Materials and Methods. The Evans-Blue (EB) leakage (OD630nm) of WT or Adm2 −/− mice was quantified, and data were presented as scatter plots with mean±SEM (n=10 mice). C-H, Data were analyzed using unpaired, 2-tailed parametric t test with Welch correction; (J and K) data were analyzed using unpaired, 2-tailed nonparametric Mann-Whitney U test; (M and N) data were analyzed using 1-way ANOVA (Kruskal-Wallis test) followed by nonparametric Dunn post hoc analysis. *P<0.05, **P<0.01, ***P<0.001. to activate ERK1/2 in ECs. It has been reported that HUVECs express CRLR and RAMP2 (receptor activity-modifying protein 2) coreceptors. 13 In this study, we found that intermedin was unable to stimulate ERK1/2 phosphorylation when CRLR was silenced, indicating that the interaction of intermedin with CRLR is indispensable for ERK1/2 activation ( Figure 6A ; Figure XI and XII in the online-only Data Supplement). β-arrestin mediates the agonist-dependent recruitment of Src kinase to GPCRs, facilitating activation of the Ras signaling cascade, which activates the downstream MAP (mitogen-activated protein) kinase ERK1/2. 28, 29 Immunoprecipitation analysis ( Figure 6B ) revealed that Src and β-arr1 (but not β-arr2 [β-arrestin2]) coprecipitated with CRLR after exposure to intermedin, whereas intermedin did not affect the integrity of the CRLR/RAMP2 heterodimer ( Figure 6C ). Src and β-arr1 exhibited a similar time course of association with CRLR, with coprecipitation peaking at 5 minutes, followed by rapid dissociation ( Figure 6D ). The silencing of CRLR reduced the coprecipitation of β-arr1 and Src ( Figure 6E ), and that of β-arr1 reduced the association of Src with CRLR ( Figure 6F ). However, the silencing of Src did not affect the association of β-arr1 with CRLR ( Figure 6G ). These results indicate that CRLR and β-arr1, but not Src, may serve as scaffold proteins of the complex. We also found that β-arr1 silencing blocked intermedin-induced ERK1/2 phosphorylation, similar to the effect of CRLR silencing ( Figure 6H ). These results demonstrated that formation of the signaling complex containing CRLR/β-arr1/Src was a prerequisite for the activation of ERK1/2. Importantly, immunoprecipitation analysis showed that intermedin induced the associations of β-arr1 and Src with CRLR in both sparse and confluent HUVECs ( Figure 6I ), indicating that the confluent state of the ECs did not affect their responsiveness to intermedin in formation of the CRLR/β-arr1/Src complex. Intermedin may use this mechanism to circumvent the contact inhibition of ECs to restore their proliferative ability.
Intermedin Stimulated the Autophosphorylation of Src, Which Is Responsible for Downstream ERK1/2 Activation
As shown in Figure 6G , Src was not required for the association of CRLR with β-arr1, but it may serve as an effector kinase in assembly of the complete signaling complex. Indeed, β-arrestins have been reported to recruit Src to GPCRs, which activate the Ras-ERK1/2 signaling cascade.
28,29 Thus, we assessed whether formation of the signaling complex leads to autophosphorylation of Src. To rule out the possibility that intermedin may only act on sparse but not confluent ECs, we used HUVECs after they had reached the confluent monolayer state in the follow-up experiments. Tyrosine 418 is located in the catalytic domain and is a critical autophosphorylation site required for the full catalytic activity of Src. Intermedin significantly increased the phosphorylation of Src-Y418, and the Src inhibitor SU6656 completely suppressed this effect ( Figure 7A ). To verify these findings in vivo, intermedin with or without SU6656 was injected into 1 eye of each neonatal mouse (the other eye was used as a control), and the retinas were dissected and stained with IB4 and anti-pSrc-Y418. As shown in Figure 7B , constitutive phospho-Src signals could be observed on the retinal vessel without the stimulation of exogenous intermedin. The level of Src phosphorylation in the vessels of IMD-KO mice was considerably reduced, compared with that in the WT mice. It suggests that the endogenous intermedin affects the base level of Src phosphorylation. After the exogenous intermedin was injected into the eye, the phospho-Src signals were markedly increased in both of the WT and KO groups. It should be noticed that intermedin could also induce Src phosphorylation in other types of cells, such as stromal cells. Therefore, the increased p-Src signals, even within the vessel area, may not all come from the ECs. The 3-dimensional reconstructed images showed that about half of the p-Src-positive signals within the vessel area came from the ECs after the stimulation of intermedin ( Figure XIII in the online-only Data Supplement). When SU6656 was injected, the phospho-Src signals in the untreated or intermedin-treated group were significantly reduced to a low level ( Figure 7B ). In addition, in CRLR-or β-arr1-silenced HUVECs, intermedin was unable to induce Src-Y418 phosphorylation ( Figure 7C ), indicating that formation of the CRLR/β-arr1/Src complex is required for the intermedin-induced autophosphorylation of Src.
We then tested whether the intermedin-induced phosphorylation of Src was required for downstream ERK1/2 activation. Time course assay showed that the phosphorylation of Src peaked at 5 minutes, after which it declined rapidly. However, the phospho-ERK1/2 level peaked at 10 minutes and decreased slowly, and it was still 2.1-fold higher than that of the control after intermedin treatment for 20 minutes ( Figure 7D and 7E) . The phosphorylation of Src was rapid and occurred before that of ERK1/2, whereas the phosphorylation of ERK1/2 had a relatively slower onset and greater persistence. The results indicate that Src phosphorylation may initiate the activation of ERK1/2. Western blot analysis showed that intermedin was unable to stimulate the phosphorylation of ERK1/2 when Src was inhibited by SU6656 or silenced by siRNA ( Figure 7F and 7G) . These results suggest that Src recruitment and phosphorylation are prerequisites for the intermedin-induced activation of ERK1/2.
Intermedin Induced the Clathrin-Mediated CRLR Endocytosis Required for the Src-ERK1/2 Signaling Cascade
The endocytosis of GPCRs on agonist stimulation is required for extracellular signal transduction. It has been reported that C, D, F, and H) were analyzed using 1-way ANOVA (Kruskal-Wallis test) followed by nonparametric Dunn post hoc analysis; data (J and L) were analyzed using unpaired, 2-tailed nonparametric Mann-Whitney U test. *P<0.05, **P<0.01, ***P<0.001. 5 human umbilical vascular ECs (HUVECs) were seeded on sterilized coverslips in 6-well plates. HUVECs with <50% confluence were considered nonconfluent (cells were sparse and were not completely surrounded by adjacent cells), whereas those with >90% confluence were considered confluent (cells were surrounded by adjacent cells and formed cell-cell contacts with each other). Nonconfluent and confluent HUVECs were treated with IMD (2 μM) or VEGF (vascular endothelial growth factor; 50 ng/mL) and stained for Ki67 (red) to observe proliferating cells and they were then stained for VE-cadherin (green) to visualize cell-cell contacts. C and D, The ratio of Ki67 + cells/total cells is presented relative to that of the control. The data were quantified using 10 randomly chosen fields from 1 well, and the statistical data were calculated from 6 wells (3 experiments performed in duplicate wells; n=6). E, HUVECs were treated with IMD or VEGF for 10 min and then subjected to Western blot assay. The density of the band for p-ERK1/2 (referred to total ERK1/2) is presented relative to that of the control. The mean level in the control group was set to 1.0; n=3. F and G, HUVECs were treated with IMD or VEGF for 10 min and then immunostained for p-ERK1/2. H and I, The p-ERK1/2 + staining (Continued ) the β-arrestin-mediated activation of ERK1/2 is intimately linked to the function of GPCRs in clathrin-coated pits in mediating endocytosis. 28, 30, 31 Cell surface biotinylation assay revealed that the amount of surface CRLR was significantly reduced by ≈61% after incubation of HUVECs with intermedin for 5 minutes ( Figure 8A ). The endocytosis of CRLR peaked at 10 minutes, and the level of surface CRLR was restored slowly thereafter ( Figure 8B ). In addition, immunoprecipitation assay demonstrated that the intermedin-induced coprecipitation of clathrin with CRLR peaked at 5 minutes, after which it rapidly declined ( Figure 8C and 8D) . The association of clathrin with CRLR was transient and occurred before the endocytosis of CRLR, indicating that clathrin may facilitate the internalization of CRLR into the cytoplasm.
We next assessed whether clathrin knockdown blocked the intermedin-induced endocytosis of CRLR. Cell surface biotinylation assay showed that intermedin was unable to induce CRLR internalization when clathrin was silenced ( Figure 8E ). In addition, intermedin lost the capability to induce the phosphorylation of Src and ERK1/2 in clathrin-silenced HUVECs ( Figure 8F and 8G) . These results suggested that clathrinmediated CRLR endocytosis was indispensable for activation of the Src-ERK1/2 signaling cascade by intermedin.
β-arrestins have been reported to function as endocytic adaptors, linking receptors to clathrin-coated pit machinery. 28, 32, 33 Immunoprecipitation and biotinylation assays revealed that β-arr1 silencing not only blocked the intermedin-induced association of clathrin with CRLR ( Figure 8H ) but also inhibited CRLR internalization ( Figure 8I ). These results suggested that β-arr1 might be the key adaptor that promotes the clathrin coating of CRLR for its internalization. On the contrary, Src silencing did not affect the CRLR/clathrin association or CRLR endocytosis ( Figure 8H and 8I ). This finding suggested that Src was the key effector kinase in the CRLR/β-arr1/Src complex but that it did not affect CRLR/clathrin association or CRLR endocytosis.
Time course analysis revealed that the coprecipitation of β-arr1 and clathrin with CRLR was increased within 5 minutes, followed by their rapid dissociation ( Figure 8J ). The phosphorylation of Src showed a similar pattern ( Figure 8J) . However, the phosphorylation of ERK1/2 had a relatively slower onset and greater persistence, similar to the trend of CRLR endocytosis, both of which peaked at 10 minutes and decreased slowly ( Figure 8J ; Figure 
Discussion
Compared with the normal blood vessel system, the tumor vasculature is structurally and functionally abnormal, containing a large number of poorly perfused or nonperfused vessel sprouts. [5] [6] [7] Because most tumors are highly vascularized, the poor blood perfusion is likely because of the poorly lumenized tumor vessels and not because of the low vessel density. Intermedin is a calcitonin family peptide that can significantly enhance tumor blood perfusion. 13 However, unlike VEGF, intermedin markedly inhibits vessel sprouting and reduces vessel density.
13,14 Thus, we anticipated that intermedin might increase blood perfusion by expanding the diameters of blood vessel lumens. In this study, we have shown that intermedin significantly promotes lumen enlargement both in vitro and in vivo and that this effect is because of an increase in EC number and not because of a change in cell shape. In addition, our data suggest an alternative way by which the quiescent ECs circumvent contact inhibition by activating the CRLR-β-arr1-Src-ERK1/2 signaling cascade ( Figure XV in the online-only Data Supplement). Through this mechanism, quiescent ECs can proliferate for the continuous expansion of vessel lumens, which eventually improves the blood perfusion of these vessels.
In this study, we addressed 2 vital questions involving vascular lumen formation: first, what is the major cellular mechanism of vascular lumen enlargement? Iruela-Arispe et al, 16 Herbert et al, 17 Potente et al, 18 and Chappell et al 34 have reviewed this process and have concurred that the EC shape change is the major cause of the formation of primitive lumens of neovessels. However, little is known about the later stage when the lumens of established vessels become further enlarged. Here, we have shown that lumen enlargement, or at least the intermedin-induced lumen expansion, is due not to EC shape change but rather to an increase in EC number resulting from their proliferation. This finding leads to another question: confluent ECs that construct blood vessels remain in physical contact with each other and are considered quiescent cells because they are considered to be in a state of contact inhibition; 4, [17] [18] [19] thus, how do the these cells regain the ability to proliferate? VEGF is considered the most potent growth factor for ECs. However, how do quiescent cells have an increased proliferation rate, despite their reduced proliferative response to VEGF? 19, 26 Herein, we have shown that intermedin induces formation of the CRLR/β-arr1/Src signaling complex in ECs and that this complex is subsequently internalized into the cytoplasm in a clathrin-dependent manner to initiate the ERK1/2 signaling cascade. Importantly, this signaling cascade was not abrogated by cell-cell contacts of ECs. Thus, our data suggest a novel mechanism that may explain how ECs overcome contact inhibition to proliferate for continuous lumen expansion.
It should be noticed that in our previous study, we showed that intermedin induces a state of EC quiescence by restraining EC response to VEGF. 13 We found that intermedin could normalize the vessel system into a well-organized vasculature Figure 5 Continued. density (referred to cell number in the field) is presented relative to that of the control. The data were quantified as described above; n=6. J, FR180204 was injected into 1 eye of each neonatal mouse to block the kinase activity of ERK1/2, and the other eye was injected with saline as a control, followed by injection with IMD (5 μg per mouse, SC) from postnatal days (P) 2 to 5, and then EdU (0.8 mg per mouse) was injected IP to label proliferating cells on P6. K, The fold change in EC proliferation and the retinal vessel lumen diameter were quantified using 10 randomly chosen fields from 1 retina, and the statistical data were calculated from 5 retinas. Data were presented as mean±SD. Data were analyzed using 1-way ANOVA (Kruskal-Wallis test) followed by nonparametric Dunn post hoc analysis. *P<0.05, **P<0.01, ***P<0.001. Figure 6 . IMD induced formation of a signaling complex composed of CRLR (calcitonin receptor-like receptor)/β-arrestin1/Src. A, Confluent human umbilical vascular ECs (HUVECs) were transfected with siR-CRLR or control siRNA. After 48 h, the HUVECs were incubated with IMD for 10 min, and then the p-ERK1/2 (extracellular signal-regulated kinase 1/2) levels were measured. The level of p-ERK1/2 (referred to total-ERK1/2) is presented relative to that of the control; n=3 (experiments), similarly hereinafter. B, Confluent HUVECs were incubated with IMD for 5, 10, or 20 min. Cell lysates were immunoprecipitated for CRLR and probed for RAMP2, β-arrestin1, β-arrestin2, Src, and CRLR (as a reference). C, The levels of coprecipitated proteins (referred to β-actin group) are presented relative to that of the control; n=3. D, Time course analysis revealed the associations of proteins with CRLR within 20 min after IMD stimulation. E-G, Confluent HUVECs were transfected with siR-CRLR, siR-β-arr1, siR-Src, or control siRNA. After 48 h, the cells were incubated with IMD for 5 min and then subjected to IP-IB to analyze the protein interactions (n=3). H, Confluent HUVECs were transfected with siR-β-arr1. After 48 h, the cells were incubated with IMD for 10 min, and the p-ERK1/2 levels were then measured (n=3). I, Sparse (<50%) and confluent (>90%) HUVECs were incubated with IMD for 5 min and then subjected to IP-IB to analyze the protein interactions. The protein levels (referred to CRLRs) are presented relative to that of the control (n=3). Data were presented as mean±SD. Data were analyzed using 1-way ANOVA (Kruskal-Wallis test) followed by nonparametric Dunn post hoc analysis. *P<0.05, **P<0.01, ***P<0.001. , 1 μL) or saline was injected into the eyes. After 5 min, mice were euthanized, and the retinas were fixed and stained with IB4 (isolectin B4; red) and anti-pSrc-Y418 (green) staining. The dashed line outlines the vessel area. The number of p-Src + dots (referred to vessel area) was presented relative to the control. Data were quantified using 10 randomly chosen (Continued ) via 2 ways: restricting excessive vessel sprouting and inducing larger vessel lumens. The activation of VEGF/VEGFR2 signaling cascade will initiate the process of EC sprouting, resulting in increased vessel density. Intermedin could reduce the EC responsiveness to VEGF by upregulating VEC expression and sustaining the integrity of VEC complex. There, we say that intermedin induces a state of EC quiescence, means that intermedin can inhibit the vessel sprouting by turning down the sensitivity of ECs to the stimulation of VEGF. In the current study, we found that other than the regulation of VEGF and VEC, intermedin itself was able to activate the quiescent ECs to proliferate for lumen expansion. In our previous study, an unsolved question was left behind: why intermedin administration resulted in larger vessel lumens?
The current study provides an answer to this question, and fills a gap in our understanding of the mechanism underlying the angiogenic activities of intermedin. Now, we may say the mechanism being intact: on one hand, intermedin reduces the responsiveness of ECs to VEGF, thus inhibits the excessive vessel sprouting; on the other hand, intermedin promotes the quiescent ECs to proliferate, thus increases the vessel diameter; the integration of the 2 leads to the vascular normalization. As for the EC proliferation, we found that intermedin could maintain a sustained growth rate of ECs both in sparse and confluent conditions. In contrast, the ECs were highly responsive to VEGF in sparse condition but showed significantly decreased growth rate when they reached confluence ( Figure 5A through 5D) . The different growth rates at different stages indicated that intermedin promoted EC proliferation through a different mechanism than VEGF. Based on the results, we would expect that the mixture of VEGF and intermedin might cause a complicated reaction of the ECs in vitro: at the sparse stage, the effect of VEGF is significantly stronger than that of intermedin, which may cover the intermedin itself-induced EC proliferation; on the contrary, at the confluent stage, although the effect of VEGF is markedly reduced, the effect of intermedin is relatively milder than that of VEGF on the sparse ECs; thus, the mixture of VEGF and intermedin might not significantly increase the proliferation rate of the confluent ECs. This is consistent with our previous observation that the combination of intermedin and VEGF slightly increased the proliferation of the confluent ECs but showed no statistical difference to using VEGF alone. 13 Intermedin has been reported to induce ERK1/2 phosphorylation. 12, 13, 35 However, the underlying mechanism has not yet been clarified. Intermedin has been reported to share the receptor CRLR with other family members, such as CGRP (calcitonin gene-related peptide) and adrenomedullin. 8, 23, 25 However, whether there is a casual relationship between CRLR activation and ERK1/2 phosphorylation and how intermedin regulates CRLR to transduce the extracellular signal downstream are still unknown. Here, we have shown that intermedin induces the association of CRLR with the adaptor protein β-arr1. β-arr2 is another key adaptor for the signal transduction of some GPCRs. Herein, β-arr2 is likely constitutively bound to CRLR, and our data showed no evidence that intermedin affected this binding. β-arr1 also serves as an endocytic adaptor to link the complex to clathrin, which facilitates internalization of the complex into the cytoplasm. According to our data, the association of CRLR/β-arr1/Src/ clathrin is rapid (within 5 minutes) and occurs before receptor complex internalization and ERK1/2 phosphorylation, which is characterized by a relatively slower onset and greater persistence. Then, the receptor complex starts to dissociate, and the components may undergo recycling or degradation ( Figure XV in the online-only Data Supplement). To the best of our knowledge, this is the first detailed report of the manner by which intermedin regulates its receptor, CRLR. The findings of this study may add complexity to our understanding of GPCR signaling and may provide a basis for more extensive studies of the mechanism of CRLR regulation.
Taken together, the results of this study and those of our previous investigation of the general activities of intermedin in angiogenesis 13, 14, 36 indicate that intermedin remodels the vessel system into a hierarchical vasculature by restricting excessive vessel sprouting and promoting lumen enlargement via EC proliferation, eventually resulting in an increased blood supply. It is likely that further therapeutic progress will require a better understanding of neovascular pathophysiology. According to our data, the modulation of intermedin activity may have therapeutic potential in the treatment of angiogenesis-associated diseases. In addition, the mechanism that we discovered by which quiescent ECs circumvent contact inhibition may provide new insights into our understanding of physiological and pathological angiogenesis.
